What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. / Sæther, Sverre Georg; Schou, Morten; Kondziella, Daniel.

I: BMC Psychiatry, Bind 17, 161, 03.05.2017.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Sæther, SG, Schou, M & Kondziella, D 2017, 'What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review', BMC Psychiatry, bind 17, 161. https://doi.org/10.1186/s12888-017-1325-z

APA

Sæther, S. G., Schou, M., & Kondziella, D. (2017). What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. BMC Psychiatry, 17, [161]. https://doi.org/10.1186/s12888-017-1325-z

Vancouver

Sæther SG, Schou M, Kondziella D. What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. BMC Psychiatry. 2017 maj 3;17. 161. https://doi.org/10.1186/s12888-017-1325-z

Author

Sæther, Sverre Georg ; Schou, Morten ; Kondziella, Daniel. / What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. I: BMC Psychiatry. 2017 ; Bind 17.

Bibtex

@article{665969f11c4247828c670a18df717ca6,
title = "What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review",
abstract = "Background: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes. Methods: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders. Results: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0{\%} to 4.9{\%}. Antibody prevalence in controls was available from three studies, ranging from 0{\%} to 2.8{\%}. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5{\%} and 0{\%} of patients with psychotic and depressive syndromes, respectively. Conclusions: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.",
keywords = "Anti-neuronal antibodies, Onconeural antibodies, Paraneoplastic neuro-psychiatric syndromes, Review",
author = "S{\ae}ther, {Sverre Georg} and Morten Schou and Daniel Kondziella",
year = "2017",
month = "5",
day = "3",
doi = "10.1186/s12888-017-1325-z",
language = "English",
volume = "17",
journal = "B M C Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review

AU - Sæther, Sverre Georg

AU - Schou, Morten

AU - Kondziella, Daniel

PY - 2017/5/3

Y1 - 2017/5/3

N2 - Background: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes. Methods: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders. Results: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively. Conclusions: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.

AB - Background: Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. We aimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatric symptoms in patients with and without paraneoplastic central nervous system syndromes. Methods: Eligible studies were selected from 1980 until February 2017 according to standardized review criteria and evaluated using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). We included studies describing the psychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies in patients with psychiatric disorders. Results: Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterized onconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence in controls was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Two cerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychotic and depressive syndromes, respectively. Conclusions: The available evidence suggests that the prevalence of well-characterized onconeural antibodies in patients with psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in select patients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.

KW - Anti-neuronal antibodies

KW - Onconeural antibodies

KW - Paraneoplastic neuro-psychiatric syndromes

KW - Review

U2 - 10.1186/s12888-017-1325-z

DO - 10.1186/s12888-017-1325-z

M3 - Review

C2 - 28468645

AN - SCOPUS:85018740319

VL - 17

JO - B M C Psychiatry

JF - B M C Psychiatry

SN - 1471-244X

M1 - 161

ER -

ID: 190434789